CADILA HEALTHCARE LIMITED									Zydus Cadila	
nnexure No.	0301-SOP-QA-0	0301-SOP-QA-00094-02					ersion No.	ion No. 7.0, CURRENT		
Annexure Title Tablet / capsule inspection 1		ecord		**						
Product Name	e	1.								
Batch No	I D	Mfg, Date		Exp. Date		Batch Size / Lot Si				
Estimated Lot Size Requiring Sampling				Sample Size					4	
1 st in	spection: 1.0 % of the	Standard Bat	tch Size	2 nd inspection: 2.0 % of the standard Batch si			size.	√as applicable		
Instruction	Document the Acc./Rej. Quantity in the below given table as per the AQL. Acc./Rej. Quantity in the below given table as per the AQL. Acc./Rej. Quantity in the below given table as per the AQL. Acc./Rej. Quantity in the below given table as per the AQL. Acc./Rej. Quantity in the below given table as per the AQL. Acc./Rej. Quantity in the below given table as per the AQL. Acc./Rej. Quantity in the below given table as per the AQL. Acc./Rej. Quantity in the below given table as per the AQL. Acc./Rej. Quantity in the below given table as per the AQL. Acc./Rej. Acc./Rej. Quantity in the below given table as per the AQL. Acc./Rej. Acc./Rej. Acc./Rej. Acc./Rej. Acc./Rej. Acc./Rej. Acc./Rej. Acc./Rej. Quantity in the below given table as per the AQL. Acc./Rej. Acc								cc. Rej.	
Product	Q. I possess in account.		Summary of				Barrantine	Acc./Rej. Documented By/ Date		
Defect^	Critical (AQL:	0.010)	Major (At	Minor (AQL 1.5)						
Accepted										
Rejected								Davista	Section /	
Results:	Types of Defect	Nos.	Types of Defect	Nos.	Types of	Defect	Nos.		eted by/Date:	
Document the defects in the table.									//	
Passes Inspection: Yes			No			N/A			√ as applicable	
Comments/ di	sposition		N/A			N/A			if not applicable	
Inspection Disposition recorded by/Date: // Reviewed By/ Date:								······································	/_//	

Note: During AQL, if capping defect observed, 100% inspection shall be recommended.